SOURCE: Crucell N.V.

November 09, 2006 08:09 ET

Crucell to Webcast Analyst Meeting on November 16, 2006

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- November 9, 2006 --

Leiden, The Netherlands, November 9, 2006 - Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX), invites investors, the media and the general public to access a live audio webcast of its Analyst Day Meeting at 2.30pm CET (8.30 am US Eastern time) on Thursday, November 16, 2006.

During the meeting, Crucell's senior management will provide a comprehensive update on the Company's programs, market development and integration.

The live audio webcast, featuring the presentation slides, can be accessed via the homepage of Crucell's website at, and will be archived and available for replay following the event. The meeting is expected to last approximately two hours.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Korea and the US. The Company employs about 900 people. For more information, please visit

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

For further information please contact:

Crucell N.V.                                For Crucell in the US:
Paul Vermeij                                Redington, Inc.
Director Investor Relations and Corporate   Thomas Redington
Communications                              Tel. +1 212-926-1733
Tel. +31-(0)71-524 8718           

Copyright © Hugin ASA 2006. All rights reserved.

Contact Information